University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Tetrafluoroethylene (CAS 116-14-3)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
kid liv hmo kid liv vsc hmo liv vsc hmo liv vsc 107m 71.9m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   hmo = hematopoietic system. kid = kidney. liv = liver. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Tetrafluoroethylene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

TETRAFLUOROETHYLENE 116-14-3 5956 M f b6c inh 95w95 TR450 : 0 400.mg 801.mg 1.60gm MXB MXB 54.0mg Z P<.0005 29.2mg 109.mg 18/48 45/48 (45/48 44/48) ---:hcs; liv:hem,hes,hpa,hpc. C --- MXA 61.3mg Z P<.0005 30.4mg 122.mg 0/48 31/48 (28/48 35/48) ---:hem,hes. S liv MXA 61.3mg Z P<.0005 c 30.4mg 122.mg 0/48 31/48 (28/48 35/48) liv:hem,hes. liv MXA 63.3mg Z P<.0005 c 32.2mg 144.mg 17/48 33/48 (29/48 28/48) liv:hpa,hpc. liv hes 66.5mg Z P<.0005 c 31.6mg 141.mg 0/48 27/48 (27/48 34/48) --- hes 66.5mg Z P<.0005 31.6mg 141.mg 0/48 27/48 (27/48 34/48) S liv hpc 80.8mg Z P<.0005 c 40.6mg 176.mg 4/48 28/48 (22/48 20/48) --- hcs 176.mg Z P<.0005 c 85.8mg 376.mg 1/48 21/48 (19/48 18/48) liv hpa 217.mg Z P<.0005 111.mg 577.mg 15/48 17/48 20/48 (15/48) S liv hem 530.mg Z P<.0005 c 164.mg 2.64gm 0/48 5/48 (2/48 1/48) --- hem 835.mg Z P<.0005 347.mg 2.69gm 0/48 5/48 4/48 (1/48) S pit pda 1.45gm * P<.006 547.mg 26.4gm 4/48 5/48 2/48 6/48 S hag ade 1.47gm * P<.002 542.mg 10.8gm 2/48 3/48 0/48 6/48 S lun MXA 1.64gm * P<.03 554.mg n.s.s. 6/48 1/48 8/48 4/48 lun:a/a,a/c,car. S TBA MXB 48.4mg Z P<.0005 26.3mg 104.mg 34/48 47/48 (45/48 46/48) liv MXB 63.3mg Z P<.0005 32.2mg 144.mg 17/48 33/48 (29/48 28/48) liv:hpa,hpb,hpc. lun MXB 1.01gm Z P<.02 324.mg n.s.s. 6/48 0/48 8/48 (4/48) lun:a/a,a/c. 5957 M m b6c inh 95w95 TR450 : 0 334.mg 669.mg 1.34gm MXB MXB 71.6mg Z P<.0005 45.3mg 123.mg 26/48 42/48 48/48 (46/48) ---:hcs; liv:hem,hes,hpa,hpc. C liv MXA 87.0mg * P<.0005 c 56.3mg 136.mg 0/48 26/48 30/48 38/48 liv:hem,hes. --- MXA 88.3mg * P<.0005 56.7mg 142.mg 2/48 27/48 30/48 38/48 ---:hem,hes. S liv MXA 91.0mg Z P<.0005 c 54.7mg 171.mg 26/48 34/48 39/48 (35/48) liv:hpa,hpc. liv hes 108.mg * P<.0005 c 69.6mg 170.mg 0/48 21/48 27/48 37/48 --- hes 109.mg * P<.0005 69.6mg 176.mg 2/48 21/48 27/48 37/48 S liv hpc 190.mg Z P<.0005 c 113.mg 361.mg 11/48 20/48 33/48 (26/48) lun MXA 216.mg Z P<.0005 110.mg 577.mg 12/48 13/48 16/48 (7/48) lun:a/a,a/c,car. S liv hpa 222.mg * P<.0005 118.mg 520.mg 17/48 17/48 12/48 20/48 S --- hem 297.mg Z P<.0005 143.mg 669.mg 0/48 11/48 6/48 (3/48) S liv hem 308.mg Z P<.0005 c 146.mg 722.mg 0/48 10/48 5/48 (2/48) lun a/a 348.mg Z P<.0005 159.mg 1.33gm 10/48 8/48 13/48 (5/48) S --- hcs 429.mg Z P<.0005 c 223.mg 868.mg 0/48 12/48 7/48 (7/48) lun MXA 830.mg * P<.005 307.mg 10.7gm 2/48 5/48 3/48 2/48 lun:a/c,car. S thy MXA 988.mg * P<.01 325.mg 73.6gm 0/48 4/48 0/48 0/48 thy:fca,fcc. S hag MXA 1.27gm * P<.04 380.mg n.s.s. 6/48 8/48 4/48 5/48 hag:ade,car. S hag ade 1.39gm * P<.05 398.mg n.s.s. 5/48 7/48 4/48 4/48 S thy fca 1.44gm * P<.03 406.mg n.s.s. 0/48 3/48 0/48 0/48 S TBA MXB 69.9mg Z P<.0005 44.0mg 124.mg 37/48 44/48 48/48 (46/48) liv MXB 91.0mg Z P<.0005 54.7mg 171.mg 26/48 34/48 39/48 (35/48) liv:hpa,hpb,hpc. lun MXB 220.mg Z P<.0005 111.mg 597.mg 12/48 12/48 16/48 (6/48) lun:a/a,a/c. 5958 R f f34 inh 24m24 TR450 : 0 93.7mg 188.mg 376.mg MXB MXB 56.3mg Z P<.0005 29.8mg 185.mg 16/50 33/50 (31/50 39/50) ---:mnl; liv:hes,hpa,hpc. C liv MXA 156.mg Z P<.0005 c 89.9mg 317.mg 0/50 7/50 12/50 (8/50) liv:hpa,hpc. --- mnl 228.mg Z P<.0005 c 127.mg 803.mg 16/50 31/50 23/50 36/50 liv hpc 251.mg Z P<.0005 c 130.mg 630.mg 0/50 4/50 9/50 (2/50) liv hpa 528.mg * P<.002 c 289.mg 2.30gm 0/50 4/50 5/50 6/50 liv hes 886.mg Z P<.005 c 326.mg 7.22gm 0/50 0/50 5/50 (1/50) --- hes 886.mg Z P<.005 326.mg 7.22gm 0/50 0/50 5/50 (1/50) S kid MXA 958.mg * P<.008 444.mg 22.2gm 0/50 3/50 1/50 5/50 kid:rua,ruc. S TBA MXB 287.mg * P<.2 106.mg n.s.s. 49/50 50/50 49/50 48/50 liv MXB 156.mg Z P<.0005 89.9mg 317.mg 0/50 7/50 12/50 (8/50) liv:hpa,hpb,hpc. 5959 R f f34 inh 24m24 TR450 with step 0 93.7mg 188.mg 376.mg kid MXA 1.31gm * P<.0005 c 729.mg 3.47gm 0/50 3/50 3/50 10/50 kid:rua,ruc. kid rua 1.51gm * P<.002 814.mg 5.72gm 0/50 3/50 3/50 8/50 S kid ruc 7.38gm * P<.03 2.23gm n.s.s. 0/50 0/50 0/50 3/50 S 5960 R m f34 inh 24m24 TR450 : 0 32.9mg 65.8mg 132.mg tes MXA 27.5mg Z P<.0005 e 16.3mg 65.5mg 39/50 40/50 48/50 47/50 tes:iab,ica. --- mnl 59.7mg * P<.01 e 27.6mg 3.51gm 34/50 43/50 38/50 31/50 liv MXA 81.6mg * P<.002 c 40.9mg 362.mg 4/50 7/50 15/50 8/50 liv:hpa,hpc. liv hpc 163.mg * P<.003 c 74.5mg 1.01gm 1/50 1/50 10/50 3/50 kid MXA 242.mg * P<.002 103.mg 876.mg 0/50 0/50 6/50 3/50 kid:rab,rua. S kid MXA 292.mg * P<.01 114.mg 25.5gm 1/50 0/50 6/50 3/50 kid:rab,rua,ruc. S liv hpa 136.mg * P<.02 55.9mg n.s.s. 3/50 6/50 8/50 5/50 S TBA MXB 35.4mg Z P<.0005 18.9mg 141.mg 48/50 49/50 50/50 46/50 liv MXB 81.6mg * P<.002 40.9mg 362.mg 4/50 7/50 15/50 8/50 liv:hpa,hpb,hpc. 5961 R m f34 inh 24m24 TR450 with step 0 32.9mg 65.8mg 132.mg kid MXA 334.mg * P<.0005 186.mg 1.22gm 2/50 4/50 9/50 13/50 kid:rab,rua. S kid MXA 367.mg * P<.003 c 191.mg 2.40gm 3/50 5/50 9/50 13/50 kid:rab,rua,ruc.

SMILES Code for Tetrafluoroethylene: F/C(F)=C(\F)F
InChI Code for Tetrafluoroethylene: InChI=1/C2F4/c3-1(4)2(5)6
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Tetrafluoroethylene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10